For much of his 17 years, Spencer Riley has lived to play basketball. This winter, his favorite sport helped the teenager get back to life. Riley was diagnosed with non-Hodgkin lymphoma in 2016 and treated at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center that summer. He underwent an intensive three-month treatment cycle: one week of … Read more
Multiple myeloma is a type of cancer that begins in plasma cells — cells in the bone marrow, that, under normal circumstances, are involved in our immune defense system and produce antibodies. In multiple myeloma, too many plasma cells (myeloma cells) build up in the bone marrow. The presence of these tumor cells in the … Read more
When Catherine Goff was diagnosed with Hodgkin lymphoma while attending college in the 1970s, it was the shock of a lifetime. Less surprising – but still life-changing – was her later diagnosis with breast cancer, a common secondary cancer for patients like Goff who received high doses of radiation therapy to the chest. Between these … Read more
Because of their increased susceptibility to the toxicities of chemotherapy, should ALL patients with Down syndrome receive modified treatment to minimize this risk? Or should they be given the same treatment as other children with ALL, to minimize the chance for relapse?
By Rich Rothman In 2013, I was facing a lengthy hospital stay after being diagnosed with a life-threatening blood cancer known as myelodysplastic syndromes (”MDS”). I had decided to proceed with a bone marrow transplant, which was thought to be the only potential cure. After being admitted to the hospital, I had intensive, round-the-clock chemotherapy … Read more
By Dana Mendes Like many high school students, I was eager to start a new chapter of my life after graduating in 2015. I had committed to play field hockey at Assumption College in Worcester, Massachusetts, that fall, and spent the summer working out alongside my new teammates – determined to prove myself on the … Read more
Leukemia is a group of cancers of the blood cells. More than 60,000 new cases of adult leukemia are estimated in the United States for 2022 and it is one of the most common types of cancers in children. These cancers are classified as either acute, which means the cancer is fast-growing, or chronic, in which cells grow … Read more
Adult histiocyte disorders are a group of rare diseases that involve an over-production of white blood cells known as histiocytes, which destroy foreign substances and protect the body from infection. In adults, Langerhans cell histiocytosis (LCH) is the most common of these diseases. LCH arises when specialized histiocytes called dendritic cells become too abundant in … Read more
Many of the secrets of why precancerous conditions sometimes become cancerous are hidden in cells’ genes. At Dana-Farber, researchers are collecting tissue samples to see if they can pry open those secrets and unlock new treatment options for certain types of blood cancers and other blood disorders. They’re also exploring whether tumor DNA floating in … Read more
For Anna Heard, the fall of 2002 was a season of change. Set to move to Boston in September to begin a master’s program at Harvard T. H. Chan School of Public Health, Heard, then 29, had a routine physical in Washington, D.C., before starting the academic year. Although her bloodwork looked “a bit funny,” … Read more
It might sound counterintuitive, but not every patient comes to Dana-Farber for cancer treatment. For example, the Institute’s experts regularly see patients seeking help with benign (non-cancerous) blood disorders. Benign blood disorders such as anemia and sickle cell disease are often treated at cancer centers because such institutions are home to experts in hematology, which … Read more
By Kathleen Barton When you get diagnosed with cancer, it kicks your butt – both the physical aspects of chemo and the general inertia that comes with this new thing you’re living with. Before my diagnosis, I was active – working, volunteering, exercising, and spending time with friends. Then some bruising and fatigue led me … Read more
Active in physical pursuits and a world traveler, Harry Beskind, MD, was surprised when he started feeling tired while on a bike ride in 2014. He had just returned home from a river trip to Portugal with his wife, and Beskind, then 82, was having trouble riding up hills on his bike. “I thought I was just … Read more
With new research in immunotherapy and targeted therapy, treatment options for blood cancer patients are rapidly expanding. Combination therapies have also caused much excitement among researchers and physicians, and ongoing clinical trials are continuing to look at new strategies that use multiple drugs for fighting these diseases. In this Cancer Conversations podcast episode, Irene Ghobrial, … Read more
The last two years have been very exciting for blood cancer research; many new targeted therapies and immunotherapies are improving treatment outcomes for patients with lymphoma, leukemia and multiple myeloma. “We’re starting to see a lot of hematologic malignancies benefit from immunotherapy,” says Irene Ghobrial, MD. “The excitement is there for so many trials and … Read more
Chris Potter was not a fan of flying, until a group of pilots he had never met transported him to his life-saving care team. Potter, then 42, was struggling through a relapse of acute lymphocytic leukemia in 2011. His cancer was not responding to treatment, and he required at least a temporary remission to handle … Read more
When Roy Jann was diagnosed with cancer in 2013, it never crossed his mind that he would be a model for the life-saving potential of venetoclax, a new type of cancer drug that had recently entered human testing. The first inkling that something was amiss had come a few weeks earlier, while Jann was biking … Read more
Updated April 13, 2015 Venetoclax, a new type of cancer drug known as a Bcl-2 inhibitor, is showing great promise against a poor-prognosis form of chronic lymphocytic leukemia (CLL), and could work in other cancers as well. Venetoclax, formerly known as ABT-199, attacks the protein molecule, Bcl-2, that allows cancer cells to survive despite signals … Read more
While lymphomas and lymphocytic leukemias are both blood disorders, they are not the same disease. The main difference between lymphomas and lymphocytic leukemias is the location of the cancer cells. In leukemia, they’re found primarily in the bone marrow and blood; in lymphoma, they exist mainly in the lymph system, a network of tissues and … Read more
The past two years have seen a surge of new treatments for blood cancers, such as lymphoma, leukemia and multiple myeloma. Research on the genetic flaws underlying specific cancer types has led to new precision drugs such as ibrutinib and idelalisib and new immunotherapy agents that are improving outcomes in many patients with difficult-to-treat forms … Read more